Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine

Новые аспекты активного таргетирования наночастиц при доставке лекарственных средств: достижения клинических исследований и соображения по проектированию наномедицинских препаратов для лечения рака
Rachel K. O’Reilly, Amanda K. Pearce
2019-08-23

active targetingcancer nanomedicineclinical translationnanoparticle drug deliverytumor localization
Nanomedicine is a promising strategy for improving clinical outcomes for cancer therapies, by improving drug efficacy through enhanced delivery to disease sites. It is of importance for ultimate clinical success to consider the contributing factors to achieving this goal, such as size, chemistry, and functionality of nanoparticle delivery systems, and how these parameters influence tumor localization and uptake. This Topical Review will first discuss the evolution and progress of nanoparticles for cancer drug delivery and the current challenges that remain to be addressed. Strategies for overcoming the limitations of passive targeting through active targeting approaches, and the current state of such nanomedicines in the clinic will be highlighted. Finally, novel approaches toward the design of active targeted nanoparticles building on our growing understanding of nanobio interactions are considered, in order to shed light on future design considerations for accelerating clinical translation of nanomedicines.
1
Clinical success of cancer nanomedicine depends on nanoparticle size, chemistry, and functionality because these parameters influence tumor localization and cellular uptake.
2
Design considerations must account for interactions between nanoparticle properties and biological environments when developing clinically viable cancer nanomedicines.
3
Emerging active-targeted nanoparticle designs increasingly incorporate knowledge of nanobio interactions to support clinical translation.
4
Passive targeting has important limitations, motivating active-targeting strategies to improve nanoparticle delivery to tumors.
5
The review summarizes the evolution, current clinical status, and remaining challenges of nanoparticle-based cancer drug delivery.

nanoparticle delivery systems for cancer drug delivery

design parameters, tumor localization and uptake, active-targeting strategies, and clinical translation of cancer nanomedicines

Publication Details
Publication Date
2019-08-23
Journal
Publisher
ISSN
Cited by
275
Access Type
Author Information
Authors
Rachel K. O’Reilly
Amanda K. Pearce
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%